Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ; MOXCON Investigators. Adverse mortal- ity effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5:659 667. 84. Habib GB, Mann DL, Zoghbi WA. Normalization of cardiac struc- ture and function after regression of cardiac hypertrophy. Am Heart J. 1994;128:333 343. 85. Schulman DS, Flores AR, Tugoen J, Dianzumba S, Reichek N. An- tihypertensive treatment in hypertensive patients with normal left ventricular mass is associated with left ventricular remodeling and improved diastolic function. Am J Cardiol. 1996;78:56 60. 86. Lee TT, Chen J, Cohen DJ, Tsao L. The association between blood pressure and mortality in patients with heart failure. Am Heart J. 2006;151:76 83. doi: 10.1016/j.ahj.2005.03.009. 87. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC; OPTI- MIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296:2217 2226. doi: 10.1001/jama.296.18.2217. 88. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ; ADHERE Scientific Advisory Committee, Study Group, and Inves- tigators. Risk stratification for in-hospital mortality in acutely de- compensated heart failure: classification and regression tree anal- ysis. JAMA. 2005;293:572 580. doi: 10.1001/jama.293.5.572. 89. Adamopoulos C, Zannad F, Fay R, Mebazaa A, Cohen-Solal A, Guize L, Juilli re Y, Alla F. Ejection fraction and blood pressure are important and interactive predictors of 4-week mortality in severe acute heart failure. Eur J Heart Fail. 2007;9:935 941. doi: 10.1016/j.ejheart.2007.06.001. 90. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O Connor CM, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Coordinators. 